Kiadis announces presentation at the 2020 Society for Immunotherapy of Cancer Annual Meeting
26 Outubro 2020 - 3:00AM
Amsterdam, The Netherlands, October 26, 2020 – Kiadis
Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and
Brussels: KDS), a clinical-stage biopharmaceutical company
developing innovative NK-cell-based medicines for the treatment of
life-threatening diseases, today announces that a poster was
accepted for presentation at the Society for Immunotherapy of
Cancer (SITC) annual meeting being held virtually from November
9-14, 2020.
The details of the poster presentation are as follows:
- Poster #454: Oncolytic Parainfluenza Virus 5
Vector Enhances Natural Killer Cell Killing of Lung Tumor Cells in
2D and 3D spheroid cultures Presenter: Namita
Varudkar Affiliation: University of Central
FloridaSession category: Combination
immunotherapiesPresentation Dates: Thursday,
November 12, 4:50-5:20 p.m. EST and Saturday, November 14,
1:00-1:30 p.m. EST
All abstracts are scheduled to be available on
the SITC website on November 9, 2020.
Posters will be on display from 8 a.m. on
Monday, Nov. 9, until the virtual poster hall closes on December
31, 2020.
Dutch Translation/Nederlandse
vertaling
Kiadis Pharma N.V.
(‘Kiadis’) is een Nederlands beursgenoteerd biotechbedrijf
dat nieuwe geneesmiddelen ontwikkelt tegen ernstige ziekten. Het
maakt daarbij gebruik van Natural Killer-cellen (NK-cellen), grote
witte bloedlichamen die de eerste verdedigingslinie in het
menselijk afweersysteem vormen tegen kankercellen en infecties.
Kiadis maakt bekend dat een zogeheten ‘poster’ is geaccepteerd voor
presentatie op de jaarlijkse (thans virtuele) bijeenkomst van de
Society for Immunotherapy of Cancer (SITC) van 9-14 november
2020.
De details van de posterpresentatie zijn:
- Poster # 454: Oncolytic Parainfluenza Virus 5
Vector Enhances Natural Killer Cell Killing of Lung Tumor Cells in
2D and 3D spheroid cultures Presentator: Namita
VarudkarAangsloten bij: University of Central
FloridaSessie categorie:
Combinatie-immunotherapieënPresentatiedata:
donderdag 12 november, 16.50-17.20 uur EST en zaterdag 14 november,
13:00 -13: 30 uur Est
Alle abstracts zijn naar verwachting beschikbaar
op 9 november 2020 op de SITC-website.
De posters zijn beschikbaar vanaf maandag 9
november 8 uur EST in de ochtend tot de sluiting van de virtuele
posterzaal op 31 december 2020.
Dit persbericht vormt een samenvatting
van het gepubliceerde Engelstalige persbericht. Bij eventuele
verschillen is de tekst van het Engelstalige persbericht altijd
leidend.
Contacts
Kiadis: Maryann
Cimino, Sr. Manager, Corporate Affairs Tel: +1 (617) 710-7305
m.cimino@kiadis.com |
LifeSpring Life Sciences
Communication:Leon Melens (Amsterdam)Tel: +31 538 16
427lmelens@lifespring.nl Optimum Strategic
Communications: Mary Clark, Supriya Mathur Tel: +44 203
950 9144 kiadis@optimumcomms.com Kiadis_Twitter Kiadis_Twitter |
About Kiadis
Founded in 1997, Kiadis is building a fully
integrated biopharmaceutical company committed to developing
innovative cell-based medicines for patients with life-threatening
diseases. With headquarters in Amsterdam, The Netherlands, and
offices and activities across the United States, Kiadis is
reimagining medicine by leveraging the natural strengths of
humanity and our collective immune system to source the best cells
for life.
Kiadis is listed on the regulated market of
Euronext Amsterdam and Euronext Brussels since July 2, 2015, under
the symbol KDS. Learn more at www.kiadis.com.
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect Kiadis' or, as appropriate, Kiadis'
officers' current expectations and projections about future events.
By their nature, forward-looking statements involve a number of
known and unknown risks, uncertainties and assumptions that could
cause actual results, performance, achievements or events to differ
materially from those expressed, anticipated or implied by the
forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
regulation, competition and technology, can cause actual events,
performance, achievements or results to differ significantly from
any anticipated or implied development. Forward-looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or projections,
or any change in events, conditions, assumptions or circumstances
on which these forward-looking statements are based. Neither Kiadis
nor its advisers or representatives nor any of its subsidiary
undertakings or any such person's officers or employees guarantees
that the assumptions underlying such forward-looking statements are
free from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.